József Janszky

József Janszky

Auto-generated profile, based on publicly available information

József Janszky

Department of Neurology, University of Pécs, Pécs, Hungary

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2016 in Epilepsia
Verified
Journal Article
Closed access
PDF file
DTDalma Tényi
Dalma Tényi
CGCsilla Gyimesi
Csilla Gyimesi
PKPéter Kupó
Péter Kupó
RHRéka Horváth
Réka Horváth
BBBeáta Bóné
Beáta Bóné
JJJózsef Janszky
József Janszky

1 March 2006 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
JJJ. Janszky
J. Janszky
HPH.W. Pannek
H.W. Pannek
AFA. Fogarasi
A. Fogarasi
BBB. Bone
B. Bone
RSR. Schulz
R. Schulz
AEA. Ebner
A. Ebner

1 February 2015 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
GPGabor Perlaki
Gabor Perlaki
GOGergely Orsi
Gergely Orsi
ASAttila Schwarcz
Attila Schwarcz
PBPeter Bodi
Peter Bodi
EPEniko Plozer
Eniko Plozer
JJJozsef Janszky
Jozsef Janszky

1 June 2011 in Epilepsy Research
Verified
Journal Article
Closed access
ÁVÁbel Velkey
Ábel Velkey
ZSZsuzsanna Siegler
Zsuzsanna Siegler
JJJózsef Janszky
József Janszky
BDBorbála Duray
Borbála Duray
AFAndrás Fogarasi
András Fogarasi

23 June 2016 in Epilepsia
Verified
Journal Article
Closed access
PDF file
DTDalma Tényi
Dalma Tényi
CGCsilla Gyimesi
Csilla Gyimesi
RHRéka Horváth
Réka Horváth
NKNorbert Kovács
Norbert Kovács
HÁHajnalka Ábrahám
Hajnalka Ábrahám
JJJózsef Janszky
József Janszky

1 January 2017 in Ideggyogyaszati Szemle
Verified
Journal Article
Closed access
PDF file
JJJózsef Janszky
József Janszky
DTDalma Tényi
Dalma Tényi
BBBeáta Bóné
Beáta Bóné
According to Hungarian guidelines, valproate - with the exception of infants and small children as well as fertile women - is the first drug of choice in generalized and unclassified epilepsies because it is effective in most seizure types and epilepsy syndromes. It is highly effective in juvenile myoclonic epilepsy. Even though it is not the first-line drug in focal epilepsies, if the first-line therapy is ineffective, it is a plausible alternative as second choice therapy, owing to its different mechanism of action. If the type of epilepsy can't be surely established, valproate is the drug of choice, as it possesses the broadest-spectrum among antiepileptic drugs. After administration of benzodiazepines, intravenously applied valproate can be a first choice therapy in all types of status epilepticus, owing to its broad-spectrum and efficacy. Valproate is the first-choice therapy in patients with glioblastoma - independently of the seizure type -, as it is likely to improve the survival rate with 2-10 months and the effectivity of chemo- and radiotherapy. Valproate is generally not suggested for fertile women, but - as it is the most effective therapy in some epilepsy syndromes -, the patient has the right to choose valproate therapy, thus undertaking the elevated risk of developmental abnormalities, for higher safety regarding seizures. If only valproate therapy owns the ability to obtain seizure freedom, then stopping its administration is not suggested, but a low dosage has to be aimed (500-600 mg/day, but not more than 1000 mg/day): according to some studies, most idiopathic generalized epilepsies can be controlled by low valproate dosage. Stopping valproate therapy in case of an ongoing pregnancy is not suggested.